Papillary Mesothelioma

Fact Checked

Well-differentiated papillary mesothelioma is a rare subtype of epithelial mesothelioma, the cancer’s most common cell type. Papillary mesothelioma is far less aggressive than other cell types. Its growth pattern is slow, and the cancer does not typically spread to other parts of the body.

Where Does Papillary Mesothelioma Develop?

The majority of well-differentiated papillary mesothelioma tumors develop in women, specifically in the abdominal cavity. Less commonly, doctors have found WDPM tumor growth on several of the body’s protective membranes, including the pleura (lining of the lungs), pericardium (heart sac) and tunica vaginalis (lining of the testes).

Is WDPM Cancerous?

From a medical standpoint, these tumors are practically benign. Studies have reported WDPM turning into malignant mesothelioma over time, although the chance of this happening is unlikely. Some people with WDPM have also experienced multiple recurrences after treatment.

A February 2019 study published in the Annals of Diagnostic Pathology observed 75 cases of WDPM diagnosed between 2000 and 2017 at Fudan University Shanghai Cancer Center in China.

Patients in the study included 58 females and 17 males ranging in age from 18 to 69 years. Of the 75 cases, only one turned cancerous.

Is There an Asbestos Connection?

At this point, researchers are unsure whether papillary mesothelioma is linked to asbestos exposure. Some patients have a history of asbestos exposure, but most do not. The cause of this disease remains poorly understood.

According to a 2019 study published in Annals of Surgical Oncology, approximately 50 cases of WDPM in the peritoneum have been described in medical literature. There are also several small case reports of WDPM of the pleura. Another study indicated that there are fewer than 20 documented cases of testicular papillary mesothelioma.

Mesothelioma Nutrition Guide

Talk to a Doctor About Your Diagnosis

We can help you or a loved one get a diagnosis or a second opinion from a mesothelioma specialist.

Get Help Now

Symptoms and Characteristics

well-differentiated papillary mesothelioma
Well-differentiated papillary mesothelioma

Many cases of well-differentiated papillary mesothelioma have no symptoms, but the disease has been known to cause pain and excessive fluid buildup in the pleura or abdomen of some patients.

WDPM of the tunica vaginalis can cause scrotal swelling or the formation of testicular lumps. In one study of 22 WDPM cases, only two patients reported to their doctors with symptoms. One patient experienced acute abdominal pain, and the other had chronic pelvic pain.

Primary Characteristics of WDPM

  • Well-differentiated tumors are low grade, meaning their cancer cells resemble healthy cells and grow and multiply at a slow rate.
  • The cancer does not invade nearby tissues or spread throughout the body.
  • In many cases, WDPM is completely inactive, showing no signs of cell division.
  • The tumor’s cells feature small, finger-like projections called papillae. These projections are lined by a single layer of flat mesothelial cells and can appear uniform, coarse or branching.
  • Papillae sometimes create round swirls of calcium known as psammoma bodies.
  • Tumors form white or grey nodules ranging from less than 1 centimeter in size to more than 3 centimeters.
  • WDPM can develop as a solitary mass or arise in many sites. The latter is known for more aggressive behavior.
  • Tumors are smaller than 1 centimeter in more than half of all cases.
Learn More About the Types of Mesothelioma

Misdiagnosis and Challenges

Because well-differentiated papillary mesothelioma rarely causes symptoms, doctors usually discover tumor growth during an unrelated pelvic or abdominal surgery. WDPM can sometimes be found with an imaging test, such as a CT scan, but this technique isn’t sensitive enough to detect tumors smaller than 1 centimeter in size.

The only definitive procedure for diagnosing WDPM and other mesotheliomas is a biopsy — the collection of a tissue sample for laboratory analysis.

It is important for doctors to collect a comprehensive sample to prevent misdiagnosis, because highly aggressive malignant mesothelioma tumors sometimes feature areas of papillary cell growth.

Doctors may confuse WDPM with several other cancers and conditions:

  • Reactive mesothelial hyperplasia
  • Adenomatoid tumor
  • Peritoneal carcinomatosis
  • Tuberculous peritonitis
  • Serous papillary carcinoma of the ovary
  • Serous papillary carcinoma of the peritoneum

Papillary Mesothelioma Treatment

With only a limited amount of research on the management of well-differentiated papillary mesothelioma, doctors have yet to reach a consensus on the most effective course of treatment.

Therapy usually involves a combination of the main types of mesothelioma treatment, including surgery, chemotherapy and radiation therapy.

Treatment options also depend on where the papillary mesothelioma tumors form.

For example, WDPM on the peritoneum may be treated with a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as HIPEC. In the 2019 study published in Annals of Surgical Oncology, 37 of the 56 patients were treated with this combination.

Asbestos.com Mesothelioma Guide

Learn About Papillary Mesothelioma in Our Free Guide

Free information, books, wristbands and more for patients and caregivers.

Request Your Guide

Prognosis and Survival Rate of Papillary Mesothelioma

The survival outlook for patients with well-differentiated papillary mesothelioma is significantly better than the prognosis of patients with most other mesothelioma cell types.

While only 5% to 10% of malignant mesothelioma patients survive five years after diagnosis, several patients with WDPM have survived for decades.

Median Survival for Well-Differentiated Papillary Mesothelioma
WDPM of the Pleura WDPM of the Peritoneum
6 years and 2 months 12 years

Sources: American Journal of Surgical Pathology, 2004; Annals of Surgical Oncology, January 2019

Find a Top Mesothelioma Attorney

Let us help
Asbestos.com Mesothelioma Packet

Get Your Free Mesothelioma Guide

Get Yours Now

Need Financial Help for Your Mesothelioma?

Find Out How

Registered Nurse and Patient Advocate

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by
Reviewed by placeholder
Medical Review By

5 Cited Article Sources

  1. Sun, M. et al. (2019, February). Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 cases.
    Retrieved from: https://www.sciencedirect.com/science/article/pii/S1092913418303204?via%3Dihub
  2. Vogin, G. et al. (2019, January 11). Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.
    Retrieved from: https://link.springer.com/article/10.1245%2Fs10434-018-07153-2
  3. Erdogan, S. et al. (2014, June). Well-Differentiated Papillary Mesothelioma of the Tunica Vaginalis: A Case Study and Review of the Literature.
    Retrieved from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087136/
  4. Malpica, A. et al. (2012). Well-differentiated Papillary Mesothelioma of the Female Peritoneum: A Clinicopathologic Study of 26 Cases.
    Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/22024662
  5. Galateau-Salle, F. et al. (2004). Well-differentiated Papillary Mesothelioma of the Pleura: A Series of 24 Cases. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/15087673
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

Share this article

Last Modified July 25, 2019

Chat live with a patient advocate now